NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
Updated: May 28, 2022
NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat subjects with cancers. They both have shown promise, but neither alone has been sufficient to cure most subjects. This study is designed to combine both T cells and antibodies to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD138 antigen (CAR138 T cells).
Sponsor
Location
United States, North Carolina
ClinicalTrials.gov Identifier: NCT03672318
Official Title: Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma
First Posted: September 14, 2018
Click here to see details on ClinicalTrials.gov
Drug: CAR138 T Cells
Autologous CD138-specific CAR T-cells (Code C162482)
ATLCAR.CD138
CAR138 T Cells
Autologous CD138-specific CAR T-cells
Autologous CD138-specific CAR T-lymphocytes
Autologous Syndecan-1-sepcific CAR T-cells
Autologous Syndecan-1-specific CAR T-lymphocytes